Pre-Open Stock Movers 04/05: (NNOX) (DMYD) (TSLA) Higher; (ACAD) (GME) (HZNO) Lower (more...)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/23/2024
- Wall St gains on bright earnings, megacaps' support
- JPMorgan is worried about further S&P 500 sell-off potential
- Oil falls back after robust EU data as Mideast tensions linger
- China acquired top-end Nvidia AI chips despite recent US ban- Reuters
- SAP Q1 results fall short of Wall Street estimates as transformation kicks off
- Fisker (FSR) Appoints Michael Healy as Chief Restructuring Officer
- Kroger (KR), Albertsons and C&S Wholesale Grocers Announce an Updated and Expanded Divestiture Plan
- Costar Group (CSGP) to Acquire Matterport (MTTR) for $5.50/sh Cash and Stock
- Jaguar Health (JAGX) Files $75M Mixed Shelf
- Apple (AAPL) PT Lowered to $210 at Morgan Stanley, 'We'd buy post-earnings weakness'
- Apple, PepsiCo, JetBlue fall premarket; Amazon, GM and UPS rise
- After-hours movers: Cadence Design Systems, Cleveland-Cliffs, Riot Platforms, and more
- Midday movers: Tesla, Li Auto and CNH Industrial fall; Salesforce rises
- Midday movers: Netflix, Super Micro fall; Paramount Global gains
- After-hours movers: Netflix, Intuitive Surgical, Nordstrom, KB Home
dMY Technology Group, Inc. II (DMYD) a 'Clear Winner' from New York Online Sports Betting - Craig-Hallum
April 7, 2021 9:37 AM EDTCraig-Hallum analyst Ryan Sigdahl reiterated a Buy rating and $30.00 price target on dMY Technology Group, Inc. II (NYSE: DMYD) (SPAC merging with Genius Sports Limited), saying it is a "clear winner" from New York online sports betting.
The analyst commented, "While... More
Goldman Sachs Downgrades Acadia Pharmaceuticals (ACAD) to Neutral, 'Looking for clarity on forward path from Type A meeting'
April 5, 2021 4:32 PM EDTGoldman Sachs analyst Salveen Richter downgraded Acadia Pharmaceuticals (NASDAQ: ACAD) from Buy to Neutral with a price target of $25.00 (from $73.00).
The analyst comments "This morning, ACAD announced that it had received a complete response letter (CRL) from the FDA for its sNDA for Nuplazid in dementia related psychosis (DRP), which was... More
